Adjunctive antithrombotic therapy during primary percutaneous coronary intervention

Keyphrases

• Early Administration 100%
• Primary Angioplasty 100%
• Primary Percutaneous Coronary Intervention 100%
• Antithrombotic Therapy 100%
• ST-elevation Myocardial Infarction (STEMI) 75%
• Glycoprotein IIb/IIIa Inhibitors 50%
• Bleeding Complications 50%
• Clopidogrel 50%
• Glycoprotein IIb 50%
• High Dose 25%
• Randomized Trial 25%
• High Risk 25%
• Improved Survival 25%
• Epicardial 25%
• Heparin 25%
• Clinical Outcomes 25%
• Unresponsiveness 25%
• Major Bleeding 25%
• Myocardial Perfusion 25%
• Mechanical Revascularization 25%
• Aspirin 25%
• Low Mortality 25%
• Clinical High Risk 25%
• Platelet Inhibition 25%
• Infarct Size 25%
• Symptom Onset 25%
• Myocardial Ischemia-reperfusion 25%
• Thrombolysis 25%
• Bivalirudin 25%
• Routine Change 25%
• Facilitation Strategies 25%
• Routine Assessment 25%

Medicine and Dentistry

• Angioplasty 100%
• Primary Percutaneous Coronary Intervention 100%
• Antithrombotic Therapy 100%
• Bleeding 50%
• Glycoprotein IIb/IIIa Inhibitors 50%
• Clopidogrel 50%
• Adenosine Diphosphate 50%
• Glycoprotein IIb 50%
• Drug Megadose 25%
• Blood Clot Lysis 25%
• Infarction 25%
• Revascularization 25%
• Heparin 25%
• Heart Muscle Perfusion 25%
• Thrombocyte Aggregation 25%
• Major Bleeding 25%
• Acetylsalicylic Acid 25%
• Heart Muscle Reperfusion 25%
• Bivalirudin 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Antithrombotic Therapy 100%
• Glycoprotein IIb 66%
• Fibrinogen Receptor 66%
• Adenosine Diphosphate 66%
• Bleeding 66%
• Clopidogrel 66%
• Infarction 33%
• Heparin 33%
• Acetylsalicylic Acid 33%
• Bivalirudin 33%